What this is
- Chagas Disease, caused by Trypanosoma cruzi, affects millions and lacks effective treatments.
- This study investigates the trypanocidal properties of from Lippia alba, focusing on citral and carvone chemotypes.
- The research evaluates how these oils and their terpenes affect different forms of the parasite.
Essence
- from Lippia alba, particularly citral, show significant against Trypanosoma cruzi, with limonene enhancing this effect. The oils induce cell death in the parasite through apoptotic-like mechanisms.
Key takeaways
- Citral chemotype oils demonstrate strong , with IC values of 14 ± 1.5 μg/mL for epimastigotes, 22 ± 1.4 μg/mL for trypomastigotes, and 74 ± 4.4 μg/mL for amastigotes.
- Limonene significantly enhances the effectiveness of citral, reducing its IC by 17× when combined with Benznidazole, indicating a potential for synergistic treatment strategies.
- The study suggests that the and their terpenes may induce cell death in T. cruzi through mechanisms resembling apoptosis, which could inform future therapeutic approaches.
Caveats
- The study's findings are based on in vitro assays, which may not fully replicate in vivo conditions. Further pre-clinical studies are necessary to validate these results.
- The oils' cytotoxicity on mammalian cells was noted, raising concerns about their safety and therapeutic window, which requires careful consideration in future applications.
Definitions
- trypanocidal activity: The ability to kill or inhibit the growth of Trypanosoma parasites.
- essential oils: Concentrated plant extracts containing volatile aromatic compounds, often used for their therapeutic properties.
AI simplified
Background
Chagas Disease is one of the most important Neglected Tropical Diseases (NTDs) worldwide, and is one of the most relevant public health problems in Latin America. This infection, caused by the hemoflagellated protozoan Trypanosoma cruzi, currently affects an estimated 7 million people in the world, with around 99% of all registered cases occurring in Central and South American countries [1]. The global costs of this disease are calculated at approximately USD $7.19 billion per year [2], with regional economic losses of almost US $1.2 billion, annually [3]. In Colombia, the prevalence of this trypanosomiasis is estimated to be within a range of 700,000 – 1,200,000 cases, with more than 8,000,000 persons at risk [4].
In regions where the condition is endemic, disease-control efforts principally centered on preventing or reducing the T. cruzi transmission cycle by vector eradication and massive blood donation screening [5]. However, bigger challenges remain; in particular, those associated with the changing epidemiological profile of the infection (diversity of vectors, reservoirs, and modes of transmission), being the most significant problem, the lack of effective therapies to cure the T. cruzi infection or to prevent the progression of the disease, principally in advanced stages.
At present, the conventional Chagas Disease treatments are etiologic, and are comprised of only two possible options, Nifurtimox (NFX) (Lampit®, Bayer) and Benznidazole (BNZ) (Rochagan® in Brazil and Radanil® in Argentina, Roche). These two treatments have remained the standard since their introduction into clinical therapy more than 40 years ago [6]. As disadvantages, these treatments are highly toxic (often accompanied by serious side effects like digestive intolerance, severe anorexia and neurological disorders) [7]; involve prolonged treatment times; and demonstrate variable trypanocidal effectiveness in acute stage (with about 80% being associated with natural resistance). They also display limited efficacy in the late phase of the infection (in which the benefits of these therapies have not clearly defined) [8, 9].
In general, these conventional therapies do not take into account the complex cascade of cellular events leading to Chagasic cardiomyopathy, which are not only associated with the parasite’s presence, but also involve exacerbated and persistent immune response (with cellular and neuronal damage) [10, 11]. These latter factors are those which govern the microvasculopathy and cardiac failure associated with the condition [10, 11].
In this regard, the research and development of new alternative therapies for Chagas Disease remain pressing concerns. New pharmacological approaches should be more efficient and selective, seeking complete parasite elimination, but with adequate modulation of the host immune response and limitation of cellular damage [11]. To this end, in the last two decades, intensive research has been focused on the study of the properties of whole extracts or compounds isolated from plants or synthesized based on natural prototypes, which have shown promising results against parasite infections [12, 13].
Essential oils (EOs) extracted from aromatic plants and their main components have been described as broad-spectrum antimicrobial agents [14], with significant anthelmintic and antiprotozoal activity [15, 16]. Some terpenes of these oils such as citral (Lippia alba and Cymbopogon citratus), caryophyllene oxide (Aframomum sceptrum, Achillea millefolium, and Piper var brachypodon), and limonene (L. origanoides and L. pedunculosa) have demonstrated efficient trypanocidal activity on extra and intracellular forms of T. cruzi [17–20]. In addition, these terpenes have been found to exhibit other interesting biological properties, such as being anti-inflammatory immunomodulators, selective antioxidants, and cytoprotectors [21–24]. The presence of citral, caryophyllene and limonene has been identified in EOs isolated from two chemotypes (Citral and Carvone) of the aromatic shrub Lippia alba (Miller) N.E. Brown (Verbenaceae), that grows in the Colombian province of Santander [21, 25]. L. alba represents the seventh species most cited in traditional Brazilian medicine [26]. The “healers” use their leaves as an infusion to treat health problems such as hypertension, digestive, colds and local wound healing [27, 28]. In the state of Boyacá, Colombia, it is frequently used as an analgesic, for digestive (diarrhea, stomach pain) and respiratory problems (flu and cough) [29]. Previous screening studies with these oils evidenced selective inhibition and cytotoxicity against trypanosomatid parasites, in vitro [30]. Taking into consideration their numerous functions, L. alba EOs and their bioactive terpenes are a promising platform for development of holistic therapies to combat Chagas Disease. This kind of approach could allow for a selective eradication of the parasite, with less toxicity (even with chemoprotection), and for controlling the host immune response, through a possible synergistic interaction of the compounds involved [22, 31, 32].
The principal goal of this work is to characterize the inhibitory properties and cellular effects of the Citral and Carvone L. alba chemotype EOs and their main bioactive terpenes on T. cruzi epimastigotes, trypomastigotes, and amastigotes cyclic forms. The IC50 was determined for each of these compounds, and possible pharmacologic interactions were defined by a matrix of combinations of the trypanocidal compounds (from Carvone chemotype: limonene and carvone; and from Citral chemotype: citral and caryophyllene oxide). The phenotype of the parasites and mammal cells treated with EOs or terpenes was followed by fluorescent and optic microscopy, flow cytometry, and DNA electrophoresis assays.
Methods
Plant material
In this study, specimens of the Citral and Carvone chemotypes of Lippia alba (Miller) N. E. Brown (Verbenaceae) were planted in the National Research Center for Agroindustrialization of Aromatic Medical and Tropical species (CENIVAM, in Spanish) located in Bucaramanga, Santander, Colombia, at an altitude of 960 m above sea level. The formal identification of the plant specimens used in this study was provided by Prof. Jorge Luis Fernández Alonso and the vouchers were deposited at the Colombian National Herbarium (Universidad Nacional de Colombia) under Herbarium Codes COL480750 and COL512077, for Carvone and Citral chemotypes of L. alba, respectively. A range of environmental and production conditions were used in order to produce 76 EOs with possible diversity in their main compounds. In this regard, the vegetal material was grown, collected, and extracted under the following factors. 1) season: defined as dry (January to March, 26.3 °C temperature, with 68.9% relative humidity, and 1.05 mm/day precipitation) and rainy (April to November, mean temperature of 24.5 °C, relative humidity of 81.3%, and 4.13 mm of daily precipitation); 2) L. alba chemotypes (53 from Carvone and 23 from Citral); 3) part of plant harvested (root, stem, fresh and mature leaves, and flowers); 4) vegetal material conditions (fresh and dry); and 5) extraction time (from 30 to 90 min).
Essential oils extraction and characterization
The oil extraction was performed by microwave-assisted hydrodistillation (MWHD), as described elsewhere [25, 29]. Briefly, a domestic microwave oven (Kendo, 2.45 GHz, 800 W) was modified with a side orifice through which an external Dean-Stark trap joined a round flask that contained the plant material (100 g) and water (0.5 L), inside the oven. Three 15 min heating periods at full power were used to perform the hydrodistillation. The Dean-Stark trap permitted to decant the essential oil from the condensate. A gas chromatograph GC 7890 (Agilent Technologies, AT, Palo Alto, CA, U.S.A.) coupled to a mass selective detector MSD 5975C (AT, Palo Alto, CA, U.S.A.), using electron impact ionization (EI, 70 eV) was used for essential oil characterization. This system included a split/splitless injector (1:30 split ratio), and a MS-ChemStation G1701-DA data system, with the WILEY, NIST and QUADLIB 2007 spectral libraries. For their GC-MS assays, individual essential oil samples (50 μL) were mixed with n-tetradecane (2 μL, internal standard) and diluted with dichloromethane to a final volume of 1.0 mL. Helium (99.9995%) was used as the carrier gas, with 155 kPa column head pressure and 27 cm s− 1 linear velocity (1 mL minute-1, at constant flow), in two columns of different polarities (DB-5MS and DB-WAX from J&W Scientific, USA). The GC oven temperature was programmed from 50 °C (5 min) to 150 °C (2 min) at 5 °C min− 1, then to 230 °C (10 min) at 5 °C min− 1. When the DB-5MS column was used, a final heating to 275 °C (15 min) at 10 °C min− 1 was added. The temperatures of the injection port, ionization chamber and of the transfer line were set at 250, 230 and 285 °C, respectively. For the polar DB-WAX column, the transfer line temperature was set at 230 °C. Mass spectra and reconstructed (total) ion chromatograms were obtained by automatic scanning in the mass range m/z 30–400 at 4.5 scan s− 1. Compound relative abundances were calculated from the chromatographic area of profiles obtained with an AT 7890 gas chromatograph provided with flame ionization detection (FID, 250 °C). The chromatographic columns, carrier gas and oven temperature programs employed in GC-FID analysis were the same as described previously for the GC-MS system. The EO compounds were identified using mass spectra and linear retention indices relative to C8-C32 n-alkanes [33]. Several terpenoid standard compounds, such as limonene, carvone, geranial, geraniol, β-caryophyllene, and β-caryophyllene oxide, obtained from Sigma-Aldrich (St. Louis, MO, U.S.A., with purities above 98%) were used. The extracted EOs were preserved at 4 °C and protected from light before GC-MS and cellular analysis. Finally, the 76 EOs were arranged into 12 groups, according to the significant differences in the percentages of their major terpenes and one oil of each group was arbitrarily selected for further biological analysis, comprising six EOs from Citral chemotype (A13, A20, A23, A24, A25, and A28), and six from the Carvone chemotype (B7, B16, B37, 2B8, 2B18, and 2B19).
Terpenes and drugs
The terpenes S (+) carvone, D (+) limonene, (−) caryophyllene oxide, and citral were purchased from Sigma-Aldrich (St. Louis, MO). The reference medication BNZ (Radanil®, Roche) was donated by Santander’s State Secretary of Health, and purified by Dr. Leonor Yamile Vargas, from the Environmental Chemistry Program at Universidad Santo Tomás de Aquino (Bucaramanga). Concentrations ranging from 1.85 to 50 μg/mL were used for epimastigote (Epi) and amastigote (Amas) assays and 0.39 to 3.12 μg/mL for trypomastigote (Tryp) assays. The oils (at a density of 0.9 g/mL) and terpene stock solutions were prepared in dimethyl-sulfoxide (DMSO, Sigma-Aldrich (St. Louis, MO)), to get a 10% (v/v) solution, without exceeding a DMSO final concentration of 0.1%, in any solution. Working solutions (3.7 to 300 μg/mL) were diluted immediately prior to use with Liver Infusion Tryptose (LIT, Becton Dickinson, FL, USA) media and Dulbecco’s Modified Eagle’s Medium (DMEM, Life Technology, CA, USA) for T. cruzi cells and Vero lineage, respectively.
Cell cultures
Vero lineage derived from African Green Monkey Kidney (Vero, ATCC CCL-81) was used for selectivity index determination and for Tryp and Amas production. These cells were grown on DMEM (Life Technology, CA, USA) media, pH: 7.4; supplemented with 10% of inactivated Fetal Bovine Serum (FBSi), 1000 U/mL of penicillin, and 100 μg/mL of streptomycin; and incubated at 37 °C with 90% humidity and a 5% CO2 atmosphere. Epi of T. cruzi I (TcI) SYLVIO-X10 strain, were donated by Dr. Marcos López-Casillas, from Fundación Cardiovascular de Colombia and grown in LIT medium (Merck) supplemented with 10% FBSi, and incubated at 28 °C. The Trypomastigotes Derived from Cells (TDC) were obtained by infection of a confluent monolayer of Vero cells with 12 day-old stationary growth phase Epi and incubated under the same conditions described above for Vero cells.
Cytotoxic activity on Vero cells
Vero cells (3 × 105 cel/mL) were incubated at 37 °C in a 5% CO2 atmosphere and at 95% humidity for 24 h to ensure the formation of a confluent monolayer. After this time, the cells were treated with the EOs or their terpenes in four different concentrations (11.1, 33.3, 100, and 300 μg/mL). Thereafter, the lineages were incubated for 70 h at 37 °C in a 5% CO2 atmosphere and re-incubated 2 more hours with WST-1 (Roche, Mannheim, Germany), after which Optical Density (OD) measurements were analyzed by spectrophotometry. The cytotoxicity percentage was calculated using [(OD450nm Control – OD450nm treatment) / OD450nm treatment)] × 100. The results were expressed as Cytotoxic Concentration 50 (CC50).
Anti-parasitic activity on T. cruzi
T. cruzi Epi (5 × 105 Epi/mL) and TDC (5 × 105 cells/mL) in the exponential growth phase were plated in a 96-well standard microplate in LIT medium (at 28 °C) and in D-MEM medium (at 37 °C in a 5% CO2 atmosphere), respectively. Both cultures were supplemented with 10% FBSi. For the trypanocidal assays, the EOs or their terpenes were added at varying concentrations (3.7 to 100 μg/mL) and incubated at the same culture conditions for 72 (Epi) or 24 h (Tryp). The growth inhibition was estimated by light microscopy through a differential count using the Trypan Blue (Gibco) dye exclusion technique. The results were expressed in terms of Inhibitory Concentration 50 (IC50) or the concentration at which parasite growth is inhibited by 50%. For Amas assays, a monolayer of Vero cells (3 × 105 cel/mL) was infected with TDC in a 1:3 cell:parasite ratio and incubated for 24 h until Amas development occurred. Then, these intracellular forms were exposed for 120 h to EOs or terpenes in a treatment applied in two doses (at 0 and 48 h), under the same conditions described above. Growth inhibition analysis was assessed in Giemsa-stained films using light microscopy to determine the infected and uninfected cell percentage in a total of 300 cells. Cells without treatment and those treated with BNZ were used as negative and positive controls, respectively.
Pharmacological interaction among terpenes on T. cruzi
A matrix of pharmacological interactions between limonene (the most selective terpene) and the other major EO terpenes was created for the three cyclic forms of T. cruzi, using the fixed-ratio isobologram method, as described previously by Fivelman et al. [34] with some modifications (Table 1). In the interaction matrix, the estimated IC50 for each terpene was used as fixed-value for the combinations. In addition, a mixture of limonene and BNZ was also evaluated.
The susceptibility evaluation was performed following the protocol described above for in vitro anti-parasitic activity. The Fractional Inhibitory Concentration (FIC) was calculated by: (Compound X (FIC) = Compound X (IC50) in combination) / (Compound X (IC50) alone); and the sum of FIC (ΣFIC) was determined by: ΣFIC = Compound X (FIC) + Compound Y (FIC). In this manner, synergistic, antagonist, or additive interactions were defined by X¯ΣCIF < 1, X¯ΣCIF > 1 or X¯ΣCIF =1, respectively [31].
| Combination ID Number | Limonene (Compound X) | Compound Y |
|---|---|---|
| 1 | 0 | 8× IC50 |
| 2 | ½ IC50 | 4× IC50 |
| 3 | IC50 | 2× IC50 |
| 4 | 2× IC50 | IC50 |
| 5 | 4× IC50 | ½ IC50 |
| 6 | 8× IC50 | 0 |
Analysis of cell death
The death phenotype was analyzed by optical and fluorescent microscopy using phase contrast (fluorescence microscopy, Nikon Eclipse Ni). The cell morphology in Epi treated with two doses of the IC50 (2xIC50), was examined by the 4 ‘,6diamidino-2, phenylindole probe (DAPI, 1 μg/mL, Sigma Aldrich) and a TUNEL assay (Molecular Probes, Invitrogen) for DNA fragmentation using a Terminal desoxynucleotidyl Transferase (TdT) label with d-UTP fluorescein. Determination of an oligonucleosomal-DNA ladder in treated parasites was also evaluated through DNA gel electrophoresis. Evaluation of the mitochondrial potential membrane in living parasites was performed with MitoTracker Red CMXRos (579 nm/599 nm emission/excitation wavelength) [35]. As a positive and negative apoptosis control, a 15 day-old Epi culture and an untreated fresh parasite culture were used, respectively.
Flow cytometry analysis
For cell death characterization, an Annexin V/Dead with SYTOX® Green (Molecular Probes, Invitrogen) kit was used following the procedure specified in the manufacturer’s instructions. The phosphatidylserine externalization was determined by employing a recombinant Annexin V conjugated to the Orange Fluorescent phycobiliprotein R-PE, and to the necrotic cells using SYTOX™ Green nucleic acid stain. Briefly, 1 × 106 Epi per mL were treated with 2xIC50 for 48 h, washed, and suspended in 1X Annexin-Binding Buffer. Next, R-PE Annexin V and SYTOX® Green Stain were added and incubated at 37 °C, 5% CO2, and 95% humidity, and analyzed in a FACSCanto II Flow Cytometer (provided by Dr. Marcos López from Fundación Cardiovascular de Colombia), with 488 nm/575 nm Excitation/Emission filters for R-PE and 503 nm/524 nm Excitation/Emission filters for SYTOX.
Statistical analysis
Each treatment was tested in triplicate in three independent assays. The IC50 and CC50 were calculated by sigmoidal regression using the statistical software Msxlfit™ (ID Business Solution). The cytotoxicity analysis and statistically-significant difference determinations were performed using a Welch’s test for analysis of variances using SPSS 15.0 Software (IBM). Multiple comparison analysis was accomplished using a Tukey test with a 95% confidence level.
Results
Chemical composition and trypanocidal activity ofEOs L. alba
This work studied the trypanocidal properties of 12 EOs isolated from Citral and Carvone L. alba chemotypes produced under an array of standardized conditions for planting, collecting and extracting of the vegetal material. A typical chromatographic profile for each chemotype essential oil, obtained by mass spectra and linear retention indices, is showed in Fig. 1a and b, for Carvone and Citral oils, respectively. The corresponding peak assignment of these chromatograms are listed in Table 2.
All the EOs presented diversity in their chemical composition, and this variety also appeared as significant differences in their trypanocidal performance on the three cyclic forms of the parasite (Epi: F = 1320.080; p = 0.000; Tryp: F = 628.786; p = 0.000; Amas: F = 853.422; p = 0.000) (Tables 3 and 4, Fig. 2a).
The best trypanocidal performance was observed in oils isolated from Citral chemotype plants, with IC50 values of 14 ± 1.5, 22 ± 1.4, and 74 ± 4.4 μg/mL on Epi, Tryp, and Amas, respectively (p < 0.05). Among these, the two lowest IC50 achieved were by A20 (9 ± 1.2 and 13.9 ± 0.9 μg/mL, on Epi and Tryp, respectively, p < 0.05) and A23 (8 ± 1.3 and 17 ± 1.3 μg/mL, on Epi and Tryp, respectively, p < 0.05) (Table 3, Fig. 2a). However, these oils also displayed a low selectivity, with high toxicity levels on Vero cells (A20: CC50= 66 ± 5.9 μg/mL; A23: CC50= 51 ± 6.2 μg/mL). Alternatively, oil A13 exhibited a significant level of anti-T. cruzi activity on the three cyclic forms (with IC50 of 17 ± 1.7 μg/mL, (SI = 7); IC50 21 ± 1.6 μg/mL, (SI = 5.7); and IC50 88 ± 5.4 μg/mL (SI = 1.4), on Epi, Tryp, and Amas, respectively); high cell death percentages (CDP) (Epi = 85 ± 1.7%; Tryp = 100%; Amas = 57 ± 3.1%; p < 0.05), at 100 μg/mL; and low toxic effect on mammal cells (CC50 120 ± 10 μg/mL) (Table 3, Fig. 2a).
In contrast, EOs extracted from Carvone chemotype plants showed higher mean IC50 values (88 ± 3.7, 45 ± 2.5, and > 150 μg/mL on Epi, Tryp, and Amas, respectively (Table 4)), with a CDP under 60%, even at high concentrations (100 μg/mL), in both Epi (mean CDP of 56 ± 2.3%) and Tryp (mean CDP of 81 ± 3.1%) forms (Table 4). Among Carvone chemotype oils, the best trypanocidal activity was demonstrated by B7 with IC50 81 ± 2.4 μg/mL, SI = 2.5, and a CDP of 60.1% on Epi forms; and IC50 37 ± 2.1 μg/mL, SI = 5.5, and a CDP of 84.5%, on Tryp stages (p < 0.05) (Table 4, Fig. 2a). On T. cruzi replicative intracellular forms, none of the Carvone oils demonstrated significant activity (mean IC50 > 150 μg/mL; mean CDP 21 ± 4.4%). Nevertheless, on host cells (Vero) these EOs exhibited lower cytotoxicity (mean CC50 of 200 ± 11 μg/mL) than Citral oils (mean CC50 of 87 ± 8.3 μg/mL) (Table 4, Fig. 2a).
Typical gas chromatography-mass spectrometry (GC-MS) profiles, in a DB-5 (60 m) column with a mass selective detector (EI. 70 eV), of essential oils obtained fromCarvone () and Citral () chemotypes by microwave-assisted hydrodistillation (MWHD). The corresponding peak identification is showed in Table Lippia alba a b 2
In vitro trypanocidal and cytotoxic activity of Citral and Carvone chemotypeessential oils () and their bioactive terpenes () on cyclic forms of. IC: Inhibitory Concentration 50 on; CC: Cytotoxic Concentration 50 on Vero Cells L. alba Trypanosoma cruzi T. cruzi a b 50 50
| Peak | Compound | LRI | Relative Quantity, % | ||
|---|---|---|---|---|---|
| DB-5MSa | DB-WAXb | Carvone (A) | Citral (B) | ||
| 1 | 6-Methyl-5-hepten-2-one | 986 | 1241 | – | 3.3 |
| 2 | β-Myrcene | 991 | 1064 | 0.8 | – |
| 3 | Limonene | 1034 | 1105 | 29.1 | 6.6 |
| 4 | -β-Ocimenetrans | 1047 | 1153 | 0.7 | 0.2 |
| 5 | Linalool | 1100 | 1453 | 0.6 | 1.9 |
| 6 | Citronellal | 1154 | 1381 | – | 1.1 |
| 7 | Borneol | 1181 | 1613 | 0.8 | – |
| 8 | -Dihydrocarvonecis | 1203 | 1517 | 0.2 | – |
| 9 | -Dihydrocarvonetrans | 1211 | 1537 | 0.2 | – |
| 10 | Nerol | 1231 | 1708 | – | 0.8 |
| 11 | Neral | 1248 | 1589 | – | 21.5 |
| 12 | Geraniol | 1252 | 1755 | – | 5.6 |
| 13 | Carvone | 1258 | 1653 | 35 | – |
| 14 | Piperitone | 1264 | 1641 | 2.4 | – |
| 15 | Geranial | 1275 | 1643 | – | 28.7 |
| 16 | Piperitenone | 1349 | 1842 | 4 | – |
| 17 | Geranyl Acetate | 1379 | 1662 | – | 1.5 |
| 18 | β-Bourboneno | 1396 | 1428 | 1.2 | – |
| 19 | β-Elemene | 1397 | 1496 | 1 | 3 |
| 20 | -β-Caryophyllenetrans | 1436 | 1506 | 0.2 | 12.1 |
| 21 | β-Gurjunene | 1444 | 1447 | 0.2 | – |
| 22 | α-Guaiene | 1447 | 1498 | – | 1.8 |
| 23 | -β-Farnesenetrans | 1456 | 1570 | 0.7 | – |
| 24 | α-Humulene | 1471 | 1580 | 0.1 | 2.7 |
| 25 | γ-Gurjunene | 1475 | 1587 | 0.4 | – |
| 26 | Germacrene D | 1486 | 1552 | 0.1 | 2.6 |
| 27 | Bicyclosesquiphellandrene | 1496 | 1624 | 8.2 | – |
| 28 | Bicyclogermacrene | 1509 | 1608 | 0.5 | – |
| 29 | α-Bulnesene | 1515 | 1627 | – | 1.4 |
| 30 | Cubebol | 1528 | 1855 | 0.5 | – |
| 31 | Germacrene-4-ol | 1591 | 1967 | 0.6 | – |
| 32 | Caryophyllene Oxide | 1600 | 1909 | – | 2.3 |
| Season | Material | EOa | ExtraTimeb | Part Plant | Chemical Composition | Epif | Trypj | Amask | Vero | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| minc | Neral % | Geraniol % | Geranial % | Caryop%d | CarOx%e | IC± SDμg/mL50gh | SIi | ICSDμg/mL50gh | SIi | IC± SDμg/mL50gh | SIi | CC± SDμg/mL50lh | ||||
| Dry | Dry | A28 | 45 | Inflm | 19.3 | 31.5 | 31.3 | 2.3 | – | 14 ± 2.6 | 7.1 | 31 ± 1.9 | 3.1 | 66 ± 4.8 | 1.5 | 97 ± 11 |
| Rainy | Fresh | A25 | 45 | ALn | 22.8 | 5.3 | 27.5 | 4.6 | 2.8 | 18 ± 0.7 | 5.3 | 19.4 ± 0.9 | 4.9 | > 33.3 | NDr | 95 ± 9.2 |
| Dry | A13 | 30 | YLo | 30.6 | – | 54.5 | 2.9 | – | 17 ± 1.7 | 7 | 21 ± 1.6 | 5.7 | 88 ± 5.4 | 1.4 | 121 ± 10.1 | |
| A20 | 30 | MLp | 32.1 | – | 54 | 4 | 2.4 | 9 ± 1.2 | 7.8 | 14 ± 0.9 | 4.7 | > 33.3 | ND | 66 ± 5.9 | ||
| A23 | 90 | ML | 28 | – | 37.8 | 6.8 | 2.9 | 8 ± 1.3 | 6.2 | 17 ± 1.3 | 3 | > 33.3 | ND | 51 ± 6.2 | ||
| A24 | 90 | ML | 24 | – | 34.3 | 2 | 5.7 | 16 ± 1.6 | 5.7 | 29 ± 1.8 | 3.1 | 69 ± 3.0 | 1.3 | 91 ± 7.1 | ||
| BNZq | – | – | – | – | – | – | – | 17 ± 0.9 | 8.2 | 1.2 ± 0.1 | 116.3 | 6 ± 0.9 | 22.4 | 139 ± 2.3 | ||
| Season | Material | EOa | ExtraTimeb | Part Plant | Chemical Composition | Epif | Trypj | Amask | Vero | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| minc | Limonene % | Carvone % | Piper%d | BCE%e | IC± SDμg/mL50gh | SIi | ICSDμg/mL50gh | SIi | IC± SDμg/mL50gh | SIi | CC± SDμg/mL50lh | ||||
| Dry | Fresh | B7 | 30 | ALm | 19.3 | 31.5 | 31.3 | 2.3 | 81 ± 2.4 | 2.5 | 37 ± 2.1 | 5.5 | > 150 | NDo | 203 ± 7.5 |
| Rainy | Dry | 2B8 | 90 | YLn | 22.8 | 5.3 | 27.5 | 4.6 | 96 ± 4.4 | 1.9 | 47 ± 3.8 | 4 | > 150 | ND | 186 ± 11.7 |
| Fresh | B16 | 90 | AL | 30.6 | – | 54.5 | 2.9 | 97 ± 3.2 | 2.2 | 57 ± 3.0 | 3.8 | > 150 | ND | 216 ± 9.6 | |
| Dry | B37 | 30 | YL | 32.1 | – | 54 | 4 | 92 ± 3.9 | 2.1 | 43 ± 1.8 | 4.5 | > 150 | ND | 196 ± 18.2 | |
| Dry | 2B18 | 45 | AL | 28 | – | 37.8 | 6.8 | 86 ± 4.8 | 1.9 | 34 ± 3.1 | 4.9 | > 150 | ND | 165 ± 10.2 | |
| Dry | 2B19 | 90 | AL | 24 | – | 34.3 | 2 | 78 ± 3.5 | 2.9 | 51 ± 1.4 | 4.4 | > 150 | ND | 226 ± 8.5 | |
Trypanocidal activity ofTerpenes L. alba
For further studies using individual compounds, four of the major terpenes were selected from the L. alba EOs from both chemotypes, Citral (citral and (−) caryophyllene oxide) and Carvone (D (+) limonene and S (+) carvone). Table 5 presents the IC50 values obtained on the three studied parasitic forms and the CC50 values estimated on Vero cells.
Among the studied terpenes, D (+) limonene exhibited the best IC50 on Tryp (IC50 9 ± 0.8 μg/mL, SI = 32.8, p < 0.05), and Amas (IC50 29 ± 0.7 μg/mL, SI = 10.3, p < 0.05) forms, (Table 5, Fig. 2b), with the most selective and the least toxic performance on mammal cells (CC50 297 ± 2.4 μg/mL, and SI = 7.1, p < 0.05), with a CC50 even lower than the reference drug (BNZ: CC50 139 ± 2.3 μg/mL). At the other end of the spectrum, S (+) carvone constituted the terpene with the worst trypanocidal activity on all evolutionary T. cruzi forms (Epi: IC50 177 ± 7.9 μg/mL, and SI = 1.4; Tryp: IC50 124 ± 7.8 μg/mL, and SI = 1.9; Amas: IC50 > 100 μg/mL) (Table 5). It is worth pointing out that all the terpenoid fractions, except carvone, were able to induce significant cell death on extracellular forms of the parasite at 50 μg/mL (Epi: CDP = 66 ± 1.9%; Tryp: CDP = 90 ± 1.2%, p < 0.05) with caryophyllene oxide being the terpene with the highest rate of death on Epi (78 ± 2.3%), and Tryp (98 ± 0.5%, p < 0.05).
| Terpenes | EpiIC± SD(μg/mL)abc50 | SId | TrypIC± SD(μg/mL)ebc50 | SId | AmasIC± SD(μg/mL)hbc50 | SId | Vero CC± SD(μg/mL)50ic |
|---|---|---|---|---|---|---|---|
| CarOxj | 30 ± 1.7 | 4.3 | 22 ± 0.3 | 5.9 | 47 ± 1.0 | 2.7 | 128 ± 4.2 |
| Limonene | 42 ± 2.5 | 7.1 | 9 ± 0.8 | 32.8 | 29 ± 0.7 | 10.3 | 297 ± 2.4 |
| Citral | 37 ± 0.7 | 2.4 | 21 ± 1 | 4.3 | 49 ± 2.3 | 1.8 | 90 ± 3.9 |
| Carvone | 177 ± 7.9 | 1.4 | 124 ± 8 | 1.9 | > 100 | NDl | 240 ± 4.1 |
| BNZk | 17 ± 0.9 | 8.2 | 1.2 ± 0.1 | 116.3 | 6.2 ± 0.9 | 22.4 | 139 ± 2.3 |
Terpene pharmacological interactions on T. cruzi
Because D (+) limonene demonstrated the best performance as a selective trypanocidal agent on all the evolutionary forms of T. cruzi, this monoterpene was selected as a fixed-compound of a pharmacological interaction matrix among terpenes and BNZ. This matrix was assembled taking the IC50 values determined previously (Table 5). Following the FIC value interpretation described by Azeredo and Soares, (2013) [31], all the evaluated interactions were found to be synergic on both extra and intracellular forms of the parasite (except limonene with carvone, with ΣFIC = 1.10 and 1.04, on Epi and Tryp, respectively) (Table 6). Figure 3 shows these pharmacological relations as isobolograms of the mean FIC of each combination. The highest synergy was exhibited by limonene/BNZ combinations (Epi: ΣFIC = 0.44; Tryp: ΣFIC = 0.42; Amas: ΣFIC = 0.58) (Table 6, Fig. 3), with the best trypanocidal performance achieved by the 4xIC50 limonene:½IC50 BNZ mixture (4 times IC50 limonene plus one half of the IC50 of BNZ), which reduced by 14, 16, and 17 times the BNZ IC50 on Amas, Epi, and Tryp, respectively. Despite its good performance, this combination also resulted in an increased cytotoxicity on Vero cells (ΣFIC = 0.54). On the other hand, limonene with caryophyllene oxide represented the second-best combination by anti-parasitic efficacy (Epi Σ FIC = 0.49; Tryp Σ FIC = 0.45; and Amas Σ FIC = 0.71), while offering an additional advantage of reduction of the individual cytotoxicity of each terpene on Vero cells (ΣFIC = 1.22) (Table 6, Fig. 3).
Pharmacological interaction isobolograms among major terpenes of the Citral and Carvone chemotypeessential oils:limonene with caryophyllene oxide;limonene with carvone;limonene with citral; andlimonene with Benznidazole (BNZ). The interaction tests were performed on Epimastigotes, Trypomastigotes and Amastigotes ofand Vero cells. Dotted lines correspond to an additive effect; points below, on, and above line indicate a synergistic, additive, and antagonistic effect, respectively L. alba T. cruzi a b c d
| Parasitic Form | Limonene + Compound | ΣFICμg/mL ± SDfg | Pharmacological interaction |
|---|---|---|---|
| Epia | CarOxd | 0.5 ± 0.13 | Synergism |
| Carvone | 1.1 ± 0.08 | Antagonism | |
| Citral | 0.7 ± 0.13 | Synergism | |
| BNZe | 0.4 ± 0.13 | Synergism | |
| Trypb | CarOxd | 0.4 ± 0.10 | Synergism |
| Carvone | 1.04 ± 0.04 | Antagonism | |
| Citral | 0.6 ± 0.10 | Synergism | |
| BNZe | 0.4 ± 0.10 | Synergism | |
| Amasc | CarOxd | 0.7 ± 0.23 | Synergism |
| Carvone | NDh | NDh | |
| Citral | 0.8 ± 0.15 | Synergism | |
| BNZe | 0.6 ± 0.13 | Synergism | |
| Vero | CarOxd | 1.2 ± 0.16 | Antagonism |
| Carvone | 1.0 ± 0.07 | Additive | |
| Citral | 1.0 ± 0.07 | Antagonism | |
| BNZe | 0.5 ± 0.18 | Synergism |
Morphological analysis onforms T. cruzi
The morphological changes induced by the treatments studied (EOs, terpenes, or BNZ, and their combinations) were analyzed by optical and fluorescent microscopy using phase contrast, and nuclear specific (DAPI) and mitochondrial membrane potential (Mitotracker Red CMXRos [35]) stains. As shown in Fig. 4, some of the tested treatments induced significant changes on parasitic morphology such as: spherical cell conformation, reduced cytoplasmic volume (Fig. 4a, DIC), mitochondrial membrane potential deplection (Fig. 4a, MitoTracker), and formation of a nuclear speckled/condensation pattern (Fig. 4a, DAPI). In one unique finding, the caryophyllene oxide treatment also caused a flagellum to be lost. Conversely, T. cruzi cells treated with BNZ displayed cellular edema and loss of cellular membrane integrity, but with conserved mitochondrial energetic potential (Fig. 4a). Under the same conditions, Vero host cells did not present visible morphological alterations (data not shown).
Cell morphology changes ofby fluorescent and optical microscopy.Cell morphology, mitochondrial membrane potential, nuclear and kinetoplast DNA ofepimastigotes after treatment with essential oils, terpenes, or BNZ.DNA fragmentation analysis by TUNEL assay onepimastigotes treated with terpenes. The preserved parasitic DNA was visualized with a blue HOECHST fluorescent probe (negative TUNEL) and the free DNA strands were observed in green (positive TUNEL).DIC: Differential Interference Contrast Microscopy;NT: No Treatment;CarOx: caryophyllene oxide;Limo: limonene;BNZ: Benznidazole;PC: Positive control: DAPI: cells stained with DAPI nuclear fluorescent stain observed in UV filter. MitoTracker: cells stained with MitoTracker Red CMXRos stain observed in an Excitation/Emission 579/599 (nm) filter. Photographs are representative of 10 observed fields Trypanosoma cruzi T. cruzi T.cruzi a b a b c d e f
DNA fragmentation
A possible endonuclease activation triggered by studied compounds (oils, terpenes or their combinations) was assessed through agarose gel DNA electrophoresis and TUNEL analyses. DNA degradation was observed by band disappearance in agarose gel (data not shown) and confirmed through green fluorescence on nuclei and kinetoplasts from Epi forms treated for 48 h with double doses at IC50 (2xIC50) of limonene, caryophyllene oxide, and the mix limonene:BNZ; with percentages of 94, 99, and 98, respectively (Fig. 4b). Non-significant fragmentation was observed on untreated Epi (Fig. 4b).
Phosphatidylserine externalization
A flow cytometry analysis was carried out to determine the general mechanism of cell death. As expected, untreated Epi showed high viability rates (99.7%) (Fig. 5a), whereas the various terpene treatments (48 h at 2xIC50) caused high percentages of cell death, with 95.7, 89.2, 78.4, and 95.9% for cayophyllene oxide, limonene, citral, and the combination limonene:BNZ, respectively (p = 0.0001). No treatment showed statistically significant levels of negative SYTOX + positive Annexin V (p > 0.05), except the apoptosis positive control (15 day-old parasite culture) (13.6%) (Fig. 5f). On the other hand, all the treated cultures displayed high percentages of positive SYTOX and positive Annexin V. These results suggest a possible trigger of a late apoptosis mechanism (Fig. 5).
Flow cytometry analysis of phosphatidylserine externalization ofepimastigotes treated with terpenes or Benznidazole.Negative control (untreated culture).caryophyllene oxide;limonene;citral;limonene:BNZ; andapoptosis positive control (15 day-old parasite culture). The flow cytometry histograms are representative of two independent experiments T. cruzi a b c d e f
Discussion
In Chagas Disease, the pathogen-specific treatments – such as BNZ – should be prescribed for acute cases and for younger patients with little or no evidence of established cardiomyopathy [36, 37]. On the other hand, recent results from global trials have questioned the benefit of these therapies in chronic patients [8, 36]. In the case of BNZ, the drug demonstrated a significant decrease of the circulating parasite load, but no substantial effect in the prevention of the clinical decline [8, 36]. Therefore, most patients with advanced T. cruzi disease receive only symptomatic treatment for cardiomyopathy or digestive symptoms. This absence of an association between parasite clearance by BNZ and the clinical progression of heart disease has been ascribed to both the restricted activity of the treatment in the inflammatory and fibrotic cardiomyopathy lesions, as well as the irreversibility of this damage [36]. Thus, alternative approaches for Chagas infection management should aim to control not only the parasite load, but also all the factors associated with cardiomyopathy progression (oxidative stress and immune effectors, among others) [36, 38].
Since parasitic protozoa are very sensitive to oxidative stress [39], the most common trypanocidal and anti-chagasic drugs like Nitroimidazoles derived (BNZ) and Nitrofurans (NFX) were developed based on their capability to induce Reactive Oxygen Species (ROS) production [40]. However, the clinical use of both medicines has been limited due to their high toxicity [41], mutagenic potential [42], the severity of their side effects [38, 41], and the lack of significant effects on clinical disease progression in the late stages of T. cruzi infection [8, 37].
In general, the development of new trypanocidal agents has been focused on the use of molecules that alter the cellular redox potential and take advantage of the scarce antioxidant defenses of the parasite [39, 40]. A similar anti-protozoal effect has been described for essential oils rich in terpenes extracted from aromatic plants [43]. In this regard, EOs derived from Cymbopogon citratus showed promising results, with low IC50 values against T. cruzi (15.5 μg/mL for Epi and Tryp; and 5.1 μg/mL for Amas) [17]. These trypanocidal effects were attributed to the high levels of the oxygenated monoterpene citral (a mixture of neral and geranial) [17]. Similar outcomes were obtained with oils extracted from a Colombian (Santander) variant of L. alba (Citral chemotype), which were rich in such terpenes as citral, geraniol, timol, and caryophyllene oxide [30].
In this work, we tested the trypanocidal and cytotoxic activity of 12 EOs, derived from two different plant chemotypes (Citral and Carvone) of L. alba, which were produced under controlled conditions of growth (geographic location, cultivation environment, and soil), plant parameters (age and part), material state (fresh or dry) and extraction conditions (time). These standardized procedures were prepared taking into consideration the recognized high phenotypical plasticity of the plant in response to genetic, environmental, and production parameters [25], which can induce significant variations in its EO constituents, as well as in their biological activities [25, 44].
In this regard, our results also confirmed significant differences in the major chemical compounds (terpenes), and trypanocidal activity of the L. alba oils produced under varying parameters (Tables 3 and 4, and Fig. 2a). While mixtures rich in citral and caryophyllene oxide (Citral chemotype EOs) achieved good performance on extracellular forms of T. cruzi (mean IC50 values of 13.6 and 21.9 μg/mL on Epi and Tryp, respectively) (Table 3); EOs of the same plant but rich in carvone and limonene (Carvone chemotype), displayed poor inhibitory results (mean IC50 values of 88.2 and 44.9 μg/mL for Epi and Tryp, respectively) (Table 4). Individual assays with a solution of citral consistently found that this compound caused an efficient arrest of the parasite’s growth with IC50 values of 37.2 and 20.8 μg/mL on Epi and Tryp, respectively (Table 5).
With respect to citral, several studies on cancer and immune cell line models have demonstrated its interesting biological properties. As an anti-tumoral, this monoterpene exhibited significant anti-proliferative effects, in vitro and in vivo [45–48] and this cell growth inhibition was ascribed to the induction of mitochondrial apoptosis pathways (through p53 activation triggered by an ROS increase) [45]. In addition, citral has also been described as anti-inflammatory agent. In lipopolysaccharide (LPS)-stimulated macrophages, this terpene was found to suppress the expression of pro-inflammatory markers such as NLRP2 (NLR Family Pyrin Domain Containing 2), Interleukin (IL) 6 and IL-1β [24], Tumoral Necrosis Factor (TNF) α [49], as well as to activate the Peroxisome Proliferator-Activated Receptor (PPAR) γ dependent-Cyclooxygenase 2 (COX2) promotor [50]. It is worth mentioning that over a range of different cells, the expression of COX2 is regulated in a variety of ways; playing an important role in tumoral genesis, inflammation, development, and circulatory homeostasis. In these activated macrophages, citral also blocks the genic expression of the LPS-induced Nitric Oxide Synthase (iNOS) [51] and, consequently, the production of Nitric Oxide (NO). It is thought that this inhibition could suppress transcriptional activation and the translocation of the nuclear factor-kappa B (NF-ƙB). These results suggest that citral is an anti-inflammatory agent whose effects could be associated with NF-ƙB suppression [51], indicating that this compound may be a promising candidate for the treatment of inflammatory conditions like Chagas Disease.
Similarly, anticancer and anti-inflammatory properties have also been attributed to caryophyllene oxide, another major and bioactive constituent of Citral chemotype L. alba EOs. On human prostate and breast cancer cells, this sesquiterpene isolated from the EOs of medicinal plants such as guava (Psidium guajava), oregano (Origanum vulgare L.), cinammon (Cinnamomum spp.), clove (Eugenia caryophyllata), and black pepper (Piper nigrum L.), inhibited constitutive survival pathways (PI3K/AKT/mTOR/S6 K1) and ROS-dependent MAPK activation during tumorigenesis; triggering apoptosis on tumoral lineages and preventing inflammation, angiogenesis, and metastasis [52]. Furthermore, on stimulated primary splenocytes, caryophyllene oxide significantly increases the Th2/Th1 coefficient [22].
In our work, caryophyllene oxide was correlated with a trypanocidal effect, being found to be one of the major components of the most trypanocidal EOs studied: A23 and A20 (L. alba citral chemotype). Similarly, Cheikh Ali et al., [18], found a minimal lethal concentration of 0.1 μg/mL for EOs extracted from Aframomum sceptrum on cyclic forms of T. brucei; this trypanocidal action being associated with the presence of caryophyllene oxide. In the present study, this compound demonstrated a significant anti-proliferative effect against T. cruzi Epi (IC50 = 29.8 μg/mL), Tryp (IC50 = 21.6 μg/mL), and Amas (IC50 = 47.4 μg/mL) (Table 5).
Another major L. alba terpene studied herein was limonene. This monoterpene is one of the main components of the Carvone chemotype oils. Due its beneficial pharmacological characteristics such as: low toxicity (used as food additive for decades) [53], high bioavailability [54], and selective anti-tumoral effect on a variety of cancer cell lines (leukemia, lymphoma, prostate, hepatic, colorectal, pancreatic, gastric, and breast, among others [54–57]); several research efforts have been undertaken with respect to this monoterpene. Interestingly, on a prostate cancer model, limonene caused apoptotic programmed cell death by the induction of a selective oxidative stress on tumoral cells [57]. As for protozoa, cancer cells are highly vulnerable to cell death induced by pro-oxidant agents (such as limonene) due their high metabolism and their deficient antioxidant mechanisms [58]. In this study, limonene was the best trypanocidal and most selective terpene with the lowest inhibitory doses (IC50 of 9.0, 28.7, and 41.8 μg/mL on Tryp, Amas, and Epi, respectively). However, this good performance was not replicated when T. cruzi forms were treated with oils rich in carvone and limonene (L. alba Carvone chemotype EOs displayed higher IC50 levels on Epi = 88.2 μg/mL, Tryp = 44.9 μg/mL, and Amas > 150 μg/mL) (Table 5). Interestingly, carvone was the least effective trypanocidal terpene, with the lowest values of cell death percentage induction and highest IC50 results (Table 5). These results were associated with the strong antioxidant capability previously ascribed to this monoterpene [59]. Accordingly, a possible antagonism seems likely between limonene and carvone (which was present in the oil mixture in levels close to 42%) (Table 4). Pharmacological interaction tests confirmed that the presence of carvone in the L. alba Carvone chemotype oils, impaired the limonene’s trypanocidal performance on T. cruzi Tryp (ΣCIF: 1.04 μg/mL) and Epi (ΣCIF: 1.10 μg/mL) forms (Table 6). In further assays, limonene presented a synergistic pharmacological interaction with the other bioactive L. alba terpenes (citral and caryophyllene oxide), and with BNZ, exhibiting ΣFIC values < 0.8 μg/mL on the three parasite forms analyzed (Table 6). In combination with BNZ, limonene caused a significant decrease of the BNZ-IC50, by 14, 16, and 17 times on Amas, Epi, and Tryp, respectively (Table 6).
These positive interactions could have been due to the simultaneal action of these compounds on diverse and additive mechanisms that lead to cell death in susceptible lineages. Such mechanisms may include: a) polymerization microtubules disruption (citral) [60]; b) endoplasmic reticulum stress induction (citral) [60]; c) PIP3/AKT survival pathway inhibition (limonene, citral, and caryophyllene oxide) [52, 61, 62]; d) oxidative stress stimulation (limonene, citral, and caryophyllene oxide) [52, 57, 63]; and e) apoptosis by caspases activation (citral and limonene) [61–63], among others.
It is important to add that the parasite cells treated for 48 h with some of the studied compounds (A23 oil, citral, caryophyllene oxide, limonene, and the mixture of limonene and BNZ) evidenced typical characteristics of apoptosis, such as cytoplasmic blebbing, cell shrinkage, flagellum absence, loss of mitochondrial membrane potential, condensation of the nuclear chromatin, and DNA fragmentation (Fig. 4a). Also, the treatment of parasites with caryophyllene oxide or limonene (alone, in combination, or with BNZ) led to positive results in TUNEL assays (Fig. 4b). Correspondingly, an impairment of membrane potential (Fig. 4) and the externalization of phosphatidylserine (Fig. 5) were observed on T. cruzi cells treated with citral, limonene, and caryophyllene oxide. These results suggest a possible activation of an early apoptosis mechanism that rapidly progresses to late apoptosis (positive SYTOX plus positive Annexin V) accompanied by DNA fragmentation. In trypanosomatids like Leishmania donovani, T. brucei, and T. cruzi, these same characteristics have been reported in parasites suffering calcium imbalance and oxidative stress (by ROS) [64], mitochondrial enzyme knockdown [65], or treatment with sterols [66]. In these studies, the previously mentioned features were associated with a possible programmed cell death such as apoptosis or autophagy [67].
In an illness with a complex pathogenesis like Chagas Disease (which involves the parasitic persistence that triggers and sustains an anti-inflammatory immune response), the use of synergic drugs (like limonene/caryophyllene oxide) with several biological advantages (significant trypanocidal activity [32], low toxicity on mammal tissues [53]; and anti-genotoxic [68], chemoprotective [23], and anti-inflammatory activity [22]) could be an interesting platform for the development of an adjuvant therapy that enhances the therapeutic effects of the conventional treatments, principally in advanced stage of the infection (probably improving trypanocidal action, reducing therapeutic doses, increasing tolerance, or retarding resistance development) [69].
Conclusions
In this work, a range of growth, plant, and extraction parameters were found to significantly influence the chemical composition and trypanocidal activity of essential oils isolated from L. alba Citral and Carvone chemotypes. L. alba Citral chemotype oils, extracted under known and controlled conditions, presented significant trypanocidal activity on three cyclic T. cruzi forms: epimastigotes, trypomastigotes, and amastigotes. Assays using pure solutions of the main terpenes that constitute L. alba EOs, confirmed an association among parasitological activity and the presence of citral and caryophyllene oxide. Tests using EOs extracted from Carvone chemotype (rich in carvone and limonene), and their most important components, established an antagonistic relationship between carvone and limonene in their trypanocidal performance. Nevertheless, in this study, the best anti-T. cruzi, and most selective, activity was achieved by limonene. Citral, caryophyllene oxide, and limonene exhibited the induction of a possible apoptotic-like phenotype. In the synergistic interaction tests, limonene also improved the trypanocidal performance of citral, caryophyllene oxide, and even BNZ, on the three parasitic forms studied. The best synergic terpene activity was displayed by the limonene and caryophyllene oxide combination. These results should be confirmed by further pre-clinical studies and could be of interest for the development of alternative and adjuvant treatments improving the tolerance and parasitological efficacy, and broadening the spectrum of the effects, of the current conventional therapies for late phases of Chagas Disease. In such research, L. alba EOs represent a renewable source for commercial exploitation of these terpenes.
Acknowledgements
This study was supported by the Vicerrectoría de Investigaciones – Universidad de Santander, under grant 005-14; and the Vicerrectoría de Investigación y Extensión – Universidad Industrial de Santander, under grant 5658. The authors would like to express their appreciation to Dr. Marcos López Casillas and to Dr. Wendy Grey Nieto Pérez for their support in flow cytometry assays; to Dr. Yamile Leonor Vargas for Benznidazole purification, and to Dr. Camilo Durán, Qm. Carlos Ramírez, and Qm. Yaride Pérez for their support during the collection and characterization of EO samples. We are grateful to Mr. Emile Blanchette for assistance in the proofreading of this study.
Funding
This research was supported by the Vicerrectoría de Investigaciones – Universidad de Santander, under grant 005–14; and the Vicerrectoría de Investigación y Extensión – Universidad Industrial de Santander, under grant 5658.
Availability of data and materials
There are no restrictions to the availability of any materials and data. The raw data are available to other researchers upon request.
Abbreviations
Authors’ contributions
LTG conceived the study, designed all the experiments, and reviewed all the results and findings. EMM performed and analyzed all the trypanocidal, cytotoxic, and cell death assays, carried out data collection and analysis, and wrote the manuscript. EES collected the plants, and extracted and chemically characterized the essential oils. SML participated in the trypanocidal, cytotoxic, and synergistic tests. All authors read, revised, and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Érika Marcela Moreno, Email: coord.maestriainfecciosas@udes.edu.co.
Sandra Milena Leal, Email: sa.leal@mail.udes.edu.co.
Elena E. Stashenko, Email: elena@tucan.uis.edu.co
Liliana Torcoroma García, Email: l.torcoroma@udes.edu.co.
References
Associated Data
Data Availability Statement
There are no restrictions to the availability of any materials and data. The raw data are available to other researchers upon request.